{'fraction_non_alphanumeric': 0.016648168701442843, 'fraction_numerical': 0.0022197558268590455, 'mean_word_length': 4.934210526315789, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy


 
 
 Inflammatory bowel disease (IBD) patients may develop anterior uveitis.
 
 
 
 An observational cohort of IBD patients followed new users of (1) tumor necrosis factor inhibitor versus nonbiologic agents or (2) adalimumab versus infliximab until occurrence of anterior uveitis or treatment change/discontinuation. Cox-proportional hazards models estimated hazard ratios in propensity score-matched cohorts of Crohn disease or ulcerative colitis patients.
 
 
 
 No statistically significant differences in the risk of uveitis were observed between initiators of nonbiologics and tumor necrosis factor inhibitor. Effect estimates for adalimumab versus infliximab were highly imprecise due to limited outcomes.
 
 
 
 Uveitis risk was not different between IBD patients treated with immunosuppressives.
